Biogen | BIIB
Stock Price
150.76
Daily Change
-2.55 -1.66%
Monthly
-3.58%
Yearly
-41.56%
Q1 Forecast
149.78



Peers Price Chg Day Year Date
AbbVie 178.51 -1.12 -0.62% 9.98% Jan/08
Acadia Pharmaceuticals 17.60 0.21 1.21% -42.60% Jan/08
ALKERMES 28.42 -0.12 -0.42% -1.93% Jan/08
Amgen 264.19 2.00 0.76% -14.02% Jan/08
Bayer 19.69 0.02 0.10% -43.37% Jan/09
Biogen 150.76 -2.55 -1.66% -41.56% Jan/08
BioMarin Pharmaceutical 68.38 0.48 0.71% -28.87% Jan/08
Bristol-Myers Squibb 56.77 -0.47 -0.82% 10.71% Jan/08
Gilead Sciences 89.11 -1.52 -1.68% 3.54% Jan/08
Incyte 73.13 -0.06 -0.08% 13.59% Jan/08
Intra Cellular Therapies 82.56 -0.67 -0.81% 16.69% Jan/08
Eli Lilly 786.28 12.30 1.59% 25.71% Jan/08
Merck 99.84 -1.24 -1.23% -15.70% Jan/08
Moderna 43.13 -4.40 -9.25% -60.86% Jan/08
Neurocrine Biosciences 138.71 1.16 0.84% 3.74% Jan/08
Novartis 91.33 0.37 0.41% -0.24% Jan/09
Pfizer 26.91 -0.19 -0.70% -8.47% Jan/08
PTC Therapeutics 45.04 0.43 0.96% 56.88% Jan/08
Ultragenyx Pharmaceutical 43.65 -0.79 -1.78% -9.72% Jan/08
Regeneron Pharmaceuticals 733.85 2.86 0.39% -18.70% Jan/08
Sanofi 95.81 0.14 0.15% 1.01% Jan/09
Sanofi 49.21 -0.78 -1.55% -4.94% Jan/08
Sarepta Therapeutics 126.27 1.78 1.43% 5.43% Jan/08
Teva Pharmaceutical Industries 7,914.00 -3.00 -0.04% 88.12% Jan/09
United Therapeutics 366.61 4.28 1.18% 63.40% Jan/08
Vertex Pharmaceuticals 412.11 3.50 0.86% -2.11% Jan/08

Indexes Price Day Year Date
US500 5911 9.22 0.16% 23.58% Jan/09
USND 19479 -10.80 -0.06% 31.10% Jan/08
US100 21133 7.92 0.04% 25.85% Jan/09

Biogen traded at $150.76 this Wednesday January 8th, decreasing $2.55 or 1.66 percent since the previous trading session. Looking back, over the last four weeks, Biogen lost 3.58 percent. Over the last 12 months, its price fell by 41.56 percent. Looking ahead, we forecast Biogen to be priced at 149.78 by the end of this quarter and at 140.63 in one year, according to Trading Economics global macro models projections and analysts expectations.

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.